326 related articles for article (PubMed ID: 22077593)
1. Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer.
Ahmed HU; Akin O; Coleman JA; Crane S; Emberton M; Goldenberg L; Hricak H; Kattan MW; Kurhanewicz J; Moore CM; Parker C; Polascik TJ; Scardino P; van As N; Villers A;
BJU Int; 2012 Jun; 109(11):1636-47. PubMed ID: 22077593
[TBL] [Abstract][Full Text] [Related]
2. Focal therapy in prostate cancer-report from a consensus panel.
de la Rosette J; Ahmed H; Barentsz J; Johansen TB; Brausi M; Emberton M; Frauscher F; Greene D; Harisinghani M; Haustermans K; Heidenreich A; Kovacs G; Mason M; Montironi R; Mouraviev V; de Reijke T; Taneja S; Thuroff S; Tombal B; Trachtenberg J; Wijkstra H; Polascik T
J Endourol; 2010 May; 24(5):775-80. PubMed ID: 20477543
[TBL] [Abstract][Full Text] [Related]
3. Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus.
Lebastchi AH; George AK; Polascik TJ; Coleman J; de la Rosette J; Turkbey B; Wood BJ; Gorin MA; Sidana A; Ghai S; Tay KJ; Ward JF; Sanchez-Salas R; Muller BG; Malavaud B; Mozer P; Crouzet S; Choyke PL; Ukimura O; Rastinehad AR; Pinto PA
Eur Urol; 2020 Sep; 78(3):371-378. PubMed ID: 32532513
[TBL] [Abstract][Full Text] [Related]
4. Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel.
Smeenge M; Barentsz J; Cosgrove D; de la Rosette J; de Reijke T; Eggener S; Frauscher F; Kovacs G; Matin SF; Mischi M; Pinto P; Rastinehad A; Rouviere O; Salomon G; Polascik T; Walz J; Wijkstra H; Marberger M
BJU Int; 2012 Oct; 110(7):942-8. PubMed ID: 22462566
[TBL] [Abstract][Full Text] [Related]
5. Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting.
Donaldson IA; Alonzi R; Barratt D; Barret E; Berge V; Bott S; Bottomley D; Eggener S; Ehdaie B; Emberton M; Hindley R; Leslie T; Miners A; McCartan N; Moore CM; Pinto P; Polascik TJ; Simmons L; van der Meulen J; Villers A; Willis S; Ahmed HU
Eur Urol; 2015 Apr; 67(4):771-7. PubMed ID: 25281389
[TBL] [Abstract][Full Text] [Related]
6. Evaluating localized prostate cancer and identifying candidates for focal therapy.
Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
[TBL] [Abstract][Full Text] [Related]
7. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.
Eggener SE; Scardino PT; Carroll PR; Zelefsky MJ; Sartor O; Hricak H; Wheeler TM; Fine SW; Trachtenberg J; Rubin MA; Ohori M; Kuroiwa K; Rossignol M; Abenhaim L;
J Urol; 2007 Dec; 178(6):2260-7. PubMed ID: 17936815
[TBL] [Abstract][Full Text] [Related]
8. A Narrative Overview of Active Surveillance for Clinically Localised Prostate Cancer.
Bates AS; Kostakopoulos N; Ayers J; Jameson M; Todd J; Lukha R; Cymes W; Chasapi D; Brown N; Bhattacharya Y; Paterson C; Lam TBL
Semin Oncol Nurs; 2020 Aug; 36(4):151045. PubMed ID: 32703714
[TBL] [Abstract][Full Text] [Related]
9. The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation.
Amin MB; Lin DW; Gore JL; Srigley JR; Samaratunga H; Egevad L; Rubin M; Nacey J; Carter HB; Klotz L; Sandler H; Zietman AL; Holden S; Montironi R; Humphrey PA; Evans AJ; Epstein JI; Delahunt B; McKenney JK; Berney D; Wheeler TM; Chinnaiyan AM; True L; Knudsen B; Hammond ME
Arch Pathol Lab Med; 2014 Oct; 138(10):1387-405. PubMed ID: 25092589
[TBL] [Abstract][Full Text] [Related]
10. Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer.
Langley S; Ahmed HU; Al-Qaisieh B; Bostwick D; Dickinson L; Veiga FG; Grimm P; Machtens S; Guedea F; Emberton M
BJU Int; 2012 Feb; 109 Suppl 1():7-16. PubMed ID: 22239224
[TBL] [Abstract][Full Text] [Related]
11. Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI.
Connor MJ; Gorin MA; Ahmed HU; Nigam R
Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):232-243. PubMed ID: 32051551
[TBL] [Abstract][Full Text] [Related]
12. Active surveillance for prostate cancer: can we modernize contemporary protocols to improve patient selection and outcomes in the focal therapy era?
Tay KJ; Mendez M; Moul JW; Polascik TJ
Curr Opin Urol; 2015 May; 25(3):185-90. PubMed ID: 25768694
[TBL] [Abstract][Full Text] [Related]
13. Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project.
Muller BG; van den Bos W; Brausi M; Fütterer JJ; Ghai S; Pinto PA; Popeneciu IV; de Reijke TM; Robertson C; de la Rosette JJ; Scionti S; Turkbey B; Wijkstra H; Ukimura O; Polascik TJ
World J Urol; 2015 Oct; 33(10):1503-9. PubMed ID: 25559111
[TBL] [Abstract][Full Text] [Related]
14. Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force.
Moore CM; Giganti F; Albertsen P; Allen C; Bangma C; Briganti A; Carroll P; Haider M; Kasivisvanathan V; Kirkham A; Klotz L; Ouzzane A; Padhani AR; Panebianco V; Pinto P; Puech P; Rannikko A; Renard-Penna R; Touijer K; Turkbey B; van Poppel H; Valdagni R; Walz J; Schoots I
Eur Urol; 2017 Apr; 71(4):648-655. PubMed ID: 27349615
[TBL] [Abstract][Full Text] [Related]
15. Candidate selection for prostate cancer focal therapy.
Taneja SS; Mason M
J Endourol; 2010 May; 24(5):835-41. PubMed ID: 20380491
[TBL] [Abstract][Full Text] [Related]
16. An evidence review of active surveillance in men with localized prostate cancer.
Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
[TBL] [Abstract][Full Text] [Related]
17. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
18. Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus.
Tan WP; Rastinehad AR; Klotz L; Carroll PR; Emberton M; Feller JF; George AK; Gill IS; Gupta RT; Katz AE; Lebastchi AH; Marks LS; Marra G; Pinto PA; Song DY; Sidana A; Ward JF; Sanchez-Salas R; Rosette J; Polascik TJ;
Urol Oncol; 2021 Nov; 39(11):781.e17-781.e24. PubMed ID: 33676851
[TBL] [Abstract][Full Text] [Related]
19. General application of the National Institute for Health and Clinical Excellence (NICE) guidance for active surveillance for men with prostate cancer is not appropriate in unscreened populations.
Wong LM; Johnston R; Sharma N; Shah NC; Warren AY; Neal DE
BJU Int; 2012 Jul; 110(1):24-7. PubMed ID: 22077729
[TBL] [Abstract][Full Text] [Related]
20. Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance.
Tosoian JJ; Mamawala M; Patel HD; Alam R; Epstein JI; Ross AE; Carter HB
J Urol; 2018 Apr; 199(4):954-960. PubMed ID: 29074222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
